A detailed history of Northern Trust Corp transactions in Compugen LTD stock. As of the latest transaction made, Northern Trust Corp holds 94,788 shares of CGEN stock, worth $155,452. This represents 0.0% of its overall portfolio holdings.

Number of Shares
94,788
Previous 100,814 5.98%
Holding current value
$155,452
Previous $260,000 38.85%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.68 - $2.52 $10,123 - $15,185
-6,026 Reduced 5.98%
94,788 $159,000
Q1 2024

May 14, 2024

SELL
$1.75 - $2.95 $22,781 - $38,403
-13,018 Reduced 11.44%
100,814 $260,000
Q4 2023

Feb 13, 2024

BUY
$0.53 - $2.0 $60,330 - $227,664
113,832 New
113,832 $225,000
Q2 2023

Aug 11, 2023

BUY
$0.57 - $1.38 $11,269 - $27,283
19,771 New
19,771 $22,000
Q2 2022

Aug 12, 2022

SELL
$1.57 - $3.33 $22,005 - $46,673
-14,016 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$2.76 - $4.64 $4,454 - $7,488
-1,614 Reduced 10.33%
14,016 $45,000
Q4 2021

Feb 08, 2022

SELL
$4.09 - $7.16 $3,852 - $6,744
-942 Reduced 5.68%
15,630 $67,000
Q3 2021

Nov 15, 2021

SELL
$5.8 - $8.02 $487,977 - $674,754
-84,134 Reduced 83.54%
16,572 $99,000
Q2 2021

Aug 13, 2021

SELL
$6.87 - $9.16 $5,619 - $7,492
-818 Reduced 0.81%
100,706 $833,000
Q1 2021

May 12, 2021

SELL
$7.67 - $13.77 $3,443 - $6,182
-449 Reduced 0.44%
101,524 $872,000
Q3 2020

Nov 16, 2020

BUY
$14.16 - $19.45 $22,429 - $30,808
1,584 Added 1.58%
101,973 $1.66 Million
Q2 2020

Aug 14, 2020

BUY
$6.97 - $17.12 $699,711 - $1.72 Million
100,389 New
100,389 $1.51 Million

Others Institutions Holding CGEN

About COMPUGEN LTD


  • Ticker CGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,624,600
  • Market Cap $142M
  • Description
  • Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...
More about CGEN
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.